- Company
- The NPS, strengthen management intervention of companies
- by Chon, Seung-Hyun Dec 31, 2019 06:45am
- The nation's largest institutional investor, the National Pension Service declared that it will actively participate in management of investment companies. Starting next year, the possibility of exercising shareholder rights, such as dismissal of directors, will be raised against “bad companies” that violate laws such as embezzlement and resig
- Company
- Pharmaceuticals produced an average of 58 drugs 2018
- by Chon, Seung-Hyun Dec 30, 2019 06:19am
- Last year, Korean pharmaceutical companies produced 58 finished drugs on average. The amount produced per item was only &8361;900 million. Among the three in 3 pharmaceutical companies, the proportion of small-scale pharmaceuticals are high, with the annual output of less than &8361;1 billion. According to the '2019 Statistical Yearbook of
- Company
- Domestic sales of Nesina & Nesina act from next year by Jeil
- by Jung, Hye-Jin Dec 30, 2019 06:19am
- Takeda's sales of Nesina and Nessina act, diabetes treatments, will be back to Jeil Pharmaceutical Co.,Ltd in eight months. According to the distribution industry on the 26th, Jeil Pharmaceutical Co.,Ltd will be in charge of sales of Takeda's DPP-4 diabetes treatment Nesina and Nesina act from January 1 next year. Takeda carried out co
- Company
- Boryeong’s copyright of anti-cancer drug,commercial value↑
- by An, Kyung-Jin Dec 27, 2019 06:28am
- The anti-cancer drug 'Zepsyre', which is owned by Boryeong in Korea, has entered the early stage of commercialization. PharmaMar, the original developer, is expected to secure the first FDA indication for small cell lung cancer by August next year. The company also won a large contract worth up to &8361;640 billion to surpass the US copyrigh
- Company
- Discontinued sales of Champix generics
- by Kim, Min-Gun Dec 27, 2019 06:27am
- Pfizer's Champix (Varenicline) salt-changing patent disputes have resulted in the loss of more than 20 domestic pharmaceutical companies, which has resulted in the suspension and recovery of generic drugs. According to the industry on the 24th, Hutecs Korea, C-tri, Danajen announced that they will be discontinued due to the result of a mat
- Company
- Kyowa Kirin Korea appoints Lee Sang Heon as next CEO
- by Eo, Yun-Ho Dec 26, 2019 06:30am
- On Dec. 20, Kyowa Kirin Korea announced the promotion of current Chief Operating Officer Lee Sang Heon (54) as a Chief Executive Officer from Jan. 2, 2020. Graduated from Seoul High School and Yonsei University majoring in bioengineering, soon-to-be CEO Lee Sang Heon had experience in marketing and business alliance in Boryung Pharmaceu
- Company
- Roche sets sail for more trials on Xofluza
- by Eo, Yun-Ho Dec 24, 2019 06:13am
- Following the two decade-long heritage of Tamiflu, next generation flu treatment Xofluza is quickly taking next steps to secure its market position. According to the related industry source on Dec. 24, Roche is to soon present two Phase 3 trial results of Korean health regulator-approved Xofluza (baloxavir), and the company also is prepp
- Company
- The NHIS again urged to pay Valsartan damages by this month
- by Chon, Seung-Hyun Dec 24, 2019 06:10am
- Health authorities urged pharmaceutical companies to pay Valsartan claims. 36 pharmaceutical companies have already filed a lawsuit that they are not liable to pay preemptively, but have reaffirmed their willingness to collect the money. According to the industry on the 20th, the National Health Insurance Service recently issued a reminder
- Company
- BMS loses the trial to revoke Eliquis’ 30% price cut
- by Kim, Jin-Gu Dec 24, 2019 06:09am
- Bristol-Myers Squibb (BMS) filed an administrative litigation to appeal against the government’s decision to lower pricing of new oral anticoagulant (NOAC) Eliquis (apixaban), but lost the case regardless. At a trial to revoke the Maximum Drug Reimbursement Price Adjustment order by the Minister of Health and Welfare on Dec. 19, Seoul A
- Company
- No more patent-evading IMD, needs new strategies
- by Kim, Jin-Gu Dec 23, 2019 06:29am
- Technically, the days of Korean pharmaceutical companies evading drug patent infringement by modifying the original’s salt base are over. The Supreme Court’s ruling on the solifenacin (trade name: Vesicare) case in the beginning of the year first showed the signs of ending drug patent infringement with incrementally modified drug (IMD)
